Revier Therapeutics has closed a €6 ($6.9) million seed financing and the launch of its operations. The company has established the first therapeutic approach to selectively target class IIa histone deacetylases (HDACs) for the treatment of cardiometabolic diseases. The financing was led by the KHAN Technology Transfer Fund II, with participation from High-Tech Gründerfonds (HTGF), […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!